This study is being done to see how well a new HIV treatment works compared to current standard treatment.
Researchers are testing a single tablet that combines bictegravir (BIC) and lenacapavir (LEN). They want to know what happens when people who are already doing well on their current HIV medicine (B/F/TAF, which is bictegravir, emtricitabine, and tenofovir alafenamide in one pill) switch to the new BIC/LEN tablet.
The main goal is to find out if switching to the new BIC/LEN pill keeps HIV under control (undetectable viral load) just as well as staying on the current B/F/TAF pill.
